Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.17 Analyst target: $1.00 Upside: 473.07%
Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor (TCR) discovery platform. The firm is dedicated to developing a diverse pipeline of TCR-based therapeutics targeting specific cancer antigens, with the objective of enhancing patient outcomes across various malignancies. With a strong intellectual property portfolio and a strategic emphasis on T cell-based immunotherapies, Tscan is well-positioned to meet significant unmet medical needs in the oncology sector, standing out in a competitive and rapidly evolving market.
See the full interactive analysis & chart →Informational only — not investment advice.